These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31215772)

  • 1. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
    Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil extracellular traps can activate alternative complement pathways.
    Wang H; Wang C; Zhao MH; Chen M
    Clin Exp Immunol; 2015 Sep; 181(3):518-27. PubMed ID: 25963026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement in ANCA-associated glomerulonephritis.
    Hilhorst M; van Paassen P; van Rie H; Bijnens N; Heerings-Rewinkel P; van Breda Vriesman P; Cohen Tervaert JW;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1302-1313. PubMed ID: 26275893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
    Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
    Antovic A; Mobarrez F; Manojlovic M; Soutari N; De Porta Baggemar V; Nordin A; Bruchfeld A; Vojinovic J; Gunnarsson I
    J Rheumatol; 2020 May; 47(5):714-721. PubMed ID: 31371653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
    Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
    Mohammad AJ; Segelmark M
    J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Gou SJ; Yuan J; Chen M; Yu F; Zhao MH
    Kidney Int; 2013 Jan; 83(1):129-37. PubMed ID: 22913983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The expression and clinical significance of neutrophil myeloperoxidase in patients with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
    Liu Y; Peng XC; Xu JN; Zheng MJ; Shuai ZW
    Zhonghua Nei Ke Za Zhi; 2022 Sep; 61(9):1016-1022. PubMed ID: 36008294
    [No Abstract]   [Full Text] [Related]  

  • 13. The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies.
    Hou X; Liu J; Wang T; Zhou J; Cui L
    J Clin Lab Anal; 2021 Feb; 35(2):e23615. PubMed ID: 33034910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.
    Gou SJ; Yuan J; Wang C; Zhao MH; Chen M
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1884-91. PubMed ID: 24115193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens.
    Tarzi RM; Liu J; Schneiter S; Hill NR; Page TH; Cook HT; Pusey CD; Woollard KJ
    Clin Exp Immunol; 2015 Jul; 181(1):65-75. PubMed ID: 25766482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
    Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study.
    Johansson L; Berglin E; Eriksson O; Mohammad AJ; Dahlqvist J; Rantapää-Dahlqvist S
    Scand J Rheumatol; 2022 May; 51(3):214-219. PubMed ID: 35048784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.
    Bonaci-Nikolic B; Andrejevic S; Pavlovic M; Dimcic Z; Ivanovic B; Nikolic M
    Clin Rheumatol; 2010 Aug; 29(8):893-904. PubMed ID: 20306213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
    Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
    Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.